-$1.45 Earnings Per Share Expected for Atara Biotherapeutics Inc (ATRA) This Quarter
Wall Street analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post earnings of ($1.45) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($1.49) and the highest is ($1.42). Atara Biotherapeutics posted earnings of ($1.15) per share during the same quarter last year, which suggests a negative year over year growth rate of 26.1%. The business is expected to report its next quarterly earnings results on Wednesday, August 7th.
According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($5.54) per share for the current financial year, with EPS estimates ranging from ($5.93) to ($5.21). For the next fiscal year, analysts anticipate that the company will report earnings of ($5.31) per share, with EPS estimates ranging from ($6.12) to ($4.63). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share for the quarter, topping the consensus estimate of ($1.48) by $0.04.
In related news, CEO Isaac E. Ciechanover sold 5,850 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $23.09, for a total transaction of $135,076.50. Following the transaction, the chief executive officer now owns 332,243 shares in the company, valued at approximately $7,671,490.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Isaac E. Ciechanover sold 7,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $24.61, for a total value of $191,958.00. Following the transaction, the chief executive officer now owns 332,243 shares in the company, valued at approximately $8,176,500.23. The disclosure for this sale can be found here. Insiders have sold a total of 63,950 shares of company stock worth $2,220,035 in the last 90 days. 10.60% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in ATRA. FMR LLC grew its stake in shares of Atara Biotherapeutics by 21.7% in the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after purchasing an additional 1,143,787 shares during the last quarter. Redmile Group LLC grew its stake in shares of Atara Biotherapeutics by 1.6% in the 1st quarter. Redmile Group LLC now owns 4,485,417 shares of the biotechnology company’s stock valued at $178,295,000 after purchasing an additional 70,800 shares during the last quarter. BlackRock Inc. grew its stake in shares of Atara Biotherapeutics by 0.6% in the 4th quarter. BlackRock Inc. now owns 3,513,235 shares of the biotechnology company’s stock valued at $122,050,000 after purchasing an additional 22,453 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Atara Biotherapeutics by 53.8% in the 1st quarter. JPMorgan Chase & Co. now owns 1,917,903 shares of the biotechnology company’s stock valued at $76,237,000 after purchasing an additional 671,216 shares during the last quarter. Finally, Neuberger Berman Group LLC grew its stake in shares of Atara Biotherapeutics by 1.3% in the 1st quarter. Neuberger Berman Group LLC now owns 1,306,651 shares of the biotechnology company’s stock valued at $51,939,000 after purchasing an additional 16,703 shares during the last quarter.
Shares of NASDAQ ATRA opened at $23.32 on Friday. The company has a current ratio of 9.96, a quick ratio of 9.96 and a debt-to-equity ratio of 0.05. Atara Biotherapeutics has a fifty-two week low of $21.61 and a fifty-two week high of $50.90. The stock has a market cap of $1.03 billion, a PE ratio of -4.43 and a beta of 2.36.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: What do I need to know about analyst ratings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.